Modified GLP-1 analogue
Semaglutide is a modified peptide analogue within the GLP-1 ligand class. Structural research describes interaction with the GLP-1 receptor as an important starting point for receptor and peptide chemistry.
Structural and signalling research
This 10 mg presentation can be documented in analytical comparisons, receptor-interaction models and research into structural features of modified GLP-1 analogues.
Scientific mechanism
Semaglutide is a modified GLP-1 analogue. In structural and cellular research systems, this ligand class binds to the GLP-1 receptor, a class B G protein-coupled receptor, allowing Gs and cAMP signalling to be studied.
Batch documentation
Before each study, always check the product label, selected presentation and batch number. Compare these details, where available, with the batch documentation and lab results.
Important research-use notice
This item is intended exclusively for controlled analytical and in-vitro laboratory research. It is not intended for human or animal consumption, use, administration, diagnosis, prevention or treatment. VLT Labs does not provide dosage, medical, health or application advice.
